Blood Pressure Assessment in Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01088269
• Other study ID #: BPM IN AF
• Status: Recruiting
• Phase: N/A
• First received: March 16, 2010
• Last updated: September 13, 2017
• Start date: March 2010
• Est. completion date: December 2017

Study information

• Verified date: September 2017
• Source: University of Athens
• Contact: George S Stergiou, MD
• Phone: +302107763117
• Email: gstergi[@]med.uoa.gr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a cross-sectional study including patients with permanent atrial fibrillation. Assessment will include:

• clinic blood pressure measurements (mercury sphygmomanometer and automated oscillometric device)

• 24-hour ambulatory blood pressure monitoring

• determination of various serum markers and cardiac ultrasound.

• evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 85 Years

Eligibility

Inclusion Criteria:

• Hypertensives adults in atrial fibrillation

Exclusion Criteria:

• Renal disease (Cr > 2 mg/l).

• Patients with pacemaker rhythm during the study.

• Each patient with acute disease (inflammation, surgery), malignancy, collagen diseases, pulmonary fibrosis, renal failure, liver failure, chronic inflammatory diseases.

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
Greece	Hypertension Center, Third Internal Medicine Dpt, University of Athens	Athens

Sponsors (1)

Lead Sponsor	Collaborator
University of Athens

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Pressure Measurement in Atrial Fibrillation,Serum Markers and echocardiographic indexes in atrial fibrillation (AF)	Evaluation of the oscillometric technique of an electronic device in blood pressure measurement.; Evaluation of the relationship of blood pressure levels with serum markers and ultrasonographic cardiac indexes.; Evaluation of a 24h ambulatory blood pressure monitoring device (Microlife WatchBPO3) in terms of its diagnostic value for the detection of atrial fibrillation compared with the reference 24h Holter ECG	Baseline